Drugs / Bone Marrow Derived MSCs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02709343 | Apr 2017 → Sep 2023 | chronic transplant rejection | The University of Queensland | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03818737 | Mar 2019 → May 2022 | osteoarthritis | Emory University | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bone Marrow Derived MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03818737 ↗ |
| Modality | Cell therapy | “Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells” NCT02709343 ↗ |
| Route | Intravenous | “given intravenously twice weekly for 2 weeks” NCT02709343 ↗ |